Warde Medical Laboratory

LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Referral Testing

Collected: 08/30/2023 14:47 Received: 08/30/2023 14:47

Test Name	Result	Flag	Ref-Ranges	Units	Site
Chlamydia Species AB Panel IgM					
Chlamydia IgM Panel Interp	See Note				ARRL

INTERPRETIVE INFORMATION: Chlamydia IgM Panel

The Chlamydia antibody test contains both species- and genus-specific antigens, and serological cross-reactions may be seen in both acute and convalescent samples (less than 1:128). A C. pneumoniae-specific reaction will exhibit titers twofold or greater than titers observed with C. trachomatis or C. psittaci serology. Ideally, acute and convalescent samples should be tested simultaneously at the same facility. If the sample submitted was collected during the acute-phase of illness, submit a marked convalescent sample within 25 days for paired testing. Seroconversion, a fourfold or greater rise in antibody titer between acute and convalescent sera, is considered strong evidence of recent infection.

The Chlamydia microimmunofluorescent assay utilizes C. psittaci, C. pneumoniae, and nine serotypes of C. trachomatis. It does not include the LGV strains of C. trachomatis.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Performed By: ARUP Laboratories
500 Chipeta Way
Salt Lake City, UT 84108
Laboratory Director: Jonathan R. Genzen, MD, PhD

C. pneumoniae IgM Titer	<1:20		<1:20	ARRL
C. psittaci IgM Titer	**1:40**	**H**	<1:20	ARRL
C. trachomatis IgM Titer	<1:20		<1:20	ARRL

Performing Site:
ARRL: ARUP REFERENCE LAB 500 Chipeta Way Salt Lake City UT 841081221

Reported Date: 2023.08.30 14:47 CHSMA

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F230000047
WX0000003827
Printed D&T: 08/30/23 14:58

Ordered By: KAJAL SITWALA, MD, PhD
WX00000000002365

Kajal V. Sitwala, MD, PhD - Medical Director
Form: MM RL1